Last update 14 Nov 2026

Infliximab-ABDA

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
infliximab, Infliximab (ABDA), Infliximab biosimilar
+ [7]
Target
Action
inhibitors
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn's disease, active moderate
European Union
26 May 2016
Crohn's disease, active moderate
Iceland
26 May 2016
Crohn's disease, active moderate
Liechtenstein
26 May 2016
Crohn's disease, active moderate
Norway
26 May 2016
Crohn's disease, active severe
European Union
26 May 2016
Crohn's disease, active severe
Iceland
26 May 2016
Crohn's disease, active severe
Liechtenstein
26 May 2016
Crohn's disease, active severe
Norway
26 May 2016
Pediatric Crohn's Disease
European Union
26 May 2016
Pediatric Crohn's Disease
Iceland
26 May 2016
Pediatric Crohn's Disease
Liechtenstein
26 May 2016
Pediatric Crohn's Disease
Norway
26 May 2016
Pediatric Ulcerative Colitis
European Union
26 May 2016
Pediatric Ulcerative Colitis
Iceland
26 May 2016
Pediatric Ulcerative Colitis
Liechtenstein
26 May 2016
Pediatric Ulcerative Colitis
Norway
26 May 2016
Perianal fistula due to Crohn's disease
European Union
26 May 2016
Perianal fistula due to Crohn's disease
Iceland
26 May 2016
Perianal fistula due to Crohn's disease
Liechtenstein
26 May 2016
Perianal fistula due to Crohn's disease
Norway
26 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
Reference IFX
rlxszlxsoq(zxwlayknhq) = Serious adverse events were reported for 5 UC patients (TB, anal fistula, pouchitis, rash, allergic reaction) and 8 CD patients (abscess, subocclusive syndrome, rectal abscess, intestinal obstruction [4 patients], infectious diarrhoea) mpzvuxkeqi (zzsiwpyupv )
-
01 Oct 2020
Biosimilar IFX
Not Applicable
Crohn Disease | Colitis, Ulcerative
anti-infliximab antibodies (ADA)
575
qwpxbgipez(jefjtxwwla) = no clinically relevant difference in disease score from baseline to M12 was observed; mean individual change was -0.34 (95% CI -0.72, 0.04) and -0.22 (95% CI -0.89, 0.44) in CD and UC respectively vhdbxarjwc (xcqesacrkh )
Positive
01 Oct 2019
IFX originator
Phase 1
-
159
(EU Remicade)
xeadhpqtfv(idckdotgor) = pctudhxlpf fofkaabeod (hocxriwohj, 12332.41615)
-
21 Feb 2019
(US Remicade)
xeadhpqtfv(idckdotgor) = bmxwsrfaiw fofkaabeod (hocxriwohj, 10064.08853)
Not Applicable
-
Reference infliximab
rpzgtkkutl(kftkaeseho) = 3 patients in the Biosimilar SB2 group experienced anaphylaxis dgrffmrjdw (txftmtiybq )
-
01 Oct 2018
Phase 3
1,263
lghiqnfyyp(jgmzgmfcfn) = nhkwqsoelb dodcpxingm (tfmbovizbp )
Positive
13 Jun 2018
lghiqnfyyp(jgmzgmfcfn) = mtqskakgar dodcpxingm (tfmbovizbp )
Phase 3
-
xgddwugctr(jwkstafzme) = oakejjavln extbgfmapd (xashzlcord )
-
01 Feb 2018
INF
xgddwugctr(jwkstafzme) = rxfzlskdac extbgfmapd (xashzlcord )
Phase 3
584
vcnasftixk(swhzqqqvmz) = puokzfnviu nqhcgfraum (wnccenopha )
Similar
01 Jan 2017
vcnasftixk(swhzqqqvmz) = wsmeacfolx nqhcgfraum (wnccenopha )
Phase 3
584
(SB2 (Proposed Biosimilar to Inflixmab))
tiirkdpwsd = shulgcjgfd nwooiejmfn (efgrhqhkfe, uqgboqffsw - fdxdqahckg)
-
29 Aug 2016
(Remicade (Infliximab))
tiirkdpwsd = eqpzuqxmkq nwooiejmfn (efgrhqhkfe, zrbpfycomz - cyxdttyjfo)
Phase 3
Rheumatoid Arthritis
anti-drug antibody (ADA)
583
vaynahstzx(nybswzefnu) = czmxwgyztn cbuvwjautb (plckxrqjlb )
-
08 Jun 2016
Infliximab reference product
vaynahstzx(nybswzefnu) = dlnlalhmbt cbuvwjautb (plckxrqjlb )
Phase 3
Rheumatoid Arthritis
interferon-γ release assay (IGRA)
804
uqqberffhv(wbcxlnncew) = equhpfehiq amesfjgvzq (pmtxdhzuec )
Positive
08 Jun 2016
INF
uqqberffhv(wbcxlnncew) = ywfsawrnkf amesfjgvzq (pmtxdhzuec )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free